Clinical Research Progress of Targeted Drug Therapy for Children with Moderate to Severe Atopic Dermatitis
10.13748/j.cnki.issn1007-7693.20232593
- VernacularTitle:靶向药物治疗儿童中重度特应性皮炎的临床研究进展
- Author:
Yan SHEN
1
;
Huawei ZHAO
2
;
Jing MIAO
2
Author Information
1. Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou 310058, China
2. Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou 310058, China；Department of Pharmacy, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
- Publication Type:Journal Article
- Keywords:
child ； atopic dermatitis ； biological agents； janus tyrosine kinase inhibitors ；phosphodiesterase-4 inhibitors； clinical trial
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(9):1287-1294
- CountryChina
- Language:Chinese
-
Abstract:
Atopic dermatitis(AD) is a chronic skin disease characterized by eczema and itching, and is one of the most common skin diseases in children. The treatment of AD is currently mainly based on drug therapy, but the treatment needs of children, especially those with moderate to severe AD, have not been fully met, safe and effective long-term treatment plans still need to be explored and practiced. Targeted drugs represented by biological agents and small molecule inhibitors are emerging drugs for the treatment of moderate to severe atopic dermatitis. Referring to relevant literature both domestically and internationally in recent years, this review focuses on two aspects: biological targeting agents and small molecule inhibitors, providing a foundation for the further development and application of targeted drugs for children with moderate to severe atopic dermatitis.
